Article Text

Download PDFPDF
Molecular epidemiology of Pseudomonas aeruginosa in an unsegregated bronchiectasis cohort sharing hospital facilities with a cystic fibrosis cohort
  1. Philip J Mitchelmore1,2,
  2. Joanna Randall3,
  3. Matthew J Bull4,
  4. Karen A Moore5,
  5. Paul A O’Neill5,
  6. Konrad Paszkiewicz5,
  7. Eshwar Mahenthiralingam4,
  8. Chris J Scotton1,
  9. Christopher D Sheldon2,
  10. Nicholas J Withers2,
  11. Alan R Brown5
  1. 1 Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, Exeter, UK
  2. 2 Department of Respiratory Medicine, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
  3. 3 Department of Microbiology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
  4. 4 Division of Organisms and Environment Research, Cardiff School of Biosciences, Cardiff University, Cardiff, UK
  5. 5 Department of Biosciences, College of Life and Environmental Sciences, University of Exeter, Exeter, UK
  1. Correspondence to Dr Philip J Mitchelmore, Department of Respiratory Medicine, Royal Devon and Exeter NHS Foundation Trust, Barrack Road, Exeter EX2 5DW, UK; pm339{at}


While Pseudomonas aeruginosa (PA) cross-infection is well documented among patients with cystic fibrosis (CF), the equivalent risk among patients with non-CF bronchiectasis (NCFB) is unclear, particularly those managed alongside patients with CF. We performed analysis of PA within a single centre that manages an unsegregated NCFB cohort alongside a segregated CF cohort. We found no evidence of cross-infection between the two cohorts or within the segregated CF cohort. However, within the unsegregated NCFB cohort, evidence of cross-infection was found between three (of 46) patients. While we do not presently advocate any change in the management of our NCFB cohort, longitudinal surveillance is clearly warranted.

  • bacterial infection
  • bronchiectasis
  • cystic Fibrosis
  • infection control
  • respiratory infection

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors PJM, CDS, NJW and ARB: study concept and design. PJM, CDS and NJW: patient recruitment. PJM, JR and KAM: methodology and investigation. PJM, MJB, PAO, KP, EM and ARB: data analysis and interpretation. PJM and ARB: writing the original draft. PJM, MJB, EM, CJS, CDS, NJW and ARB: writing, reviewing and editing the manuscript.

  • Funding This study was funded though charitable donations and a Small Grants Award by the Research and Development department at the Royal Devon and Exeter NHS Foundation Trust. The funding sources had no input into this study or its submission for publication.

  • Competing interests EM declares a grant from AlgiPharma AS held as a service contract on a CF clinical trial (unrelated to this work).

  • Patient consent Obtained.

  • Ethics approval Ethical approval for the study of our NCFB cohort was obtained through the NRES Committee South West- Exeter (14/SW/0080). Our CF samples and data were collected through the RD&E tissue bank (11/SW/0018).

  • Provenance and peer review Not commissioned; externally peer reviewed.